TY  - SOUND
AU  - Lalezari,Jacob
TI  - Development of PRO-140 (Leronlimab) as a treatment for COVID-19
T2  - Interviews on Covid-19,
PY  - 2020///
CY  - London
PB  - Henry Stewart Talks
KW  - Coronavirus infections
KW  - Treatment
KW  - COVID-19 (Disease)
KW  - Drug development
KW  - CCR5 Receptor Antagonists
KW  - therapeutic use
KW  - Coronavirus Infections
KW  - drug therapy
KW  - COVID-19
KW  - Drug Development
KW  - Inflammation
KW  - leronlimab
KW  - Pharmaceutical Preparations
KW  - Receptors, CCR5
KW  - SARS-CoV-2
N1  - Audio interview; Title from title frames; Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?; Access restricted to subscribers
UR  - https://hstalks.com/bs/4246/
UR  - https://hstalks.com/bs/p/1060/
ER  -